Aripiprazole acts as a selective dopamine D2 receptor partial agonist

被引：61
|
作者：
Wood, Martyn [1 ]
Reavill, Charlie [1 ]
机构：
[1] GlaxoSmithKline Schizophrenia & Bipolar Neurophys, Psychiat CEDD, Harlow CM19 5AW, Essex, England
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2007年 / 16卷 / 06期
关键词：
D O I：
10.1517/13543784.16.6.771
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. It has been claimed that partial agonism of the dopamine D-2 and 5-HT1A receptors and antagonism of the 5-HT2 receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser. However, recent studies have questioned the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole. This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine D, receptor and does not affect 5-HT receptors at therapeutic doses.
引用
收藏
页码：771 / 775
页数：5
相关论文
共 50 条
  • [21] PET evaluation of the dopamine D2 receptor agonist
    Finnem, SJ
    Seneca, N
    Gulyas, B
    Sovago, J
    Farde, L
    Innis, RB
    Wikstrom, HV
    Halldin, C
    NEUROIMAGE, 2004, 22 : T175 - T175
  • [22] The partial agonist of the dopamine receptor 2, Aripiprazole, facilitates extinction in adolescent rats
    Ganella, D. E.
    Madsen, H. B.
    Zbukvic, I. C.
    Coulthard, R. W.
    Lee-Kardashyan, L.
    Lawrence, A. J.
    Kim, J. H.
    JOURNAL OF NEUROCHEMISTRY, 2014, 130 : 35 - 35
  • [23] The Synthesis of a Dopamine D2 Partial Agonist for the Treatment of Schizophrenia
    Magano, Javier
    Acciacca, Alison
    Akin, Anne
    Collman, Benjamin M.
    Conway, Brian
    Waldo, Michael
    Chen, Michael H.
    Mennen, Kenneth E.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2009, 13 (03) : 555 - 566
  • [24] Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration
    Wee, Sunmee
    Wang, Zhixia
    Woolverton, William L.
    Pulvirenti, Luigi
    Koob, George F.
    NEUROPSYCHOPHARMACOLOGY, 2007, 32 (10) : 2238 - 2247
  • [25] Effect of Aripiprazole, a Partial Dopamine D2 Receptor Agonist, on Increased Rate of Methamphetamine Self-Administration in Rats with Prolonged Session Duration
    Sunmee Wee
    Zhixia Wang
    William L Woolverton
    Luigi Pulvirenti
    George F Koob
    Neuropsychopharmacology, 2007, 32 : 2238 - 2247
  • [26] Interactions of the novel antipsychotic, aripiprazole, at the D2 dopamine receptor.
    Prioleau, C
    Lawler, CP
    Mailman, RB
    FASEB JOURNAL, 1998, 12 (04): : A456 - A456
  • [27] Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways
    Jonathan D Urban
    Gabriel A Vargas
    Mark von Zastrow
    Richard B Mailman
    Neuropsychopharmacology, 2007, 32 : 67 - 77
  • [28] Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways
    Urban, Jonathan D.
    Vargas, Gabriel A.
    von Zastrow, Mark
    Mailman, Richard B.
    NEUROPSYCHOPHARMACOLOGY, 2007, 32 (01) : 67 - 77
  • [29] Effects of Dopamine D2 Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-11C]DOPA
    Ito, Hiroshi
    Takano, Harumasa
    Arakawa, Ryosuke
    Takahashi, Hidehiko
    Kodaka, Fumitoshi
    Takahata, Keisuke
    Nogami, Tsuyoshi
    Suzuki, Masayuki
    Suhara, Tetsuya
    PLOS ONE, 2012, 7 (09):
  • [30] The dopamine-serotonin system stabilizer aripiprazole is a partial agonist at D2 and 5-HT1A receptors
    Jordan, S
    Robert, MD
    Frank, YD
    Tetsuro, K
    BIOLOGICAL PSYCHIATRY, 2003, 53 (08) : 183S - 183S
12345